2025. Real-World Clinician- and Patient-Reported Outcomes and Treatment Persistence Following Bimekizumab Initiation in Patients with Psoriasis: 6-Month Results from the PPD CorEvitas Psoriasis Registry. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s632. DOI:https://doi.org/10.25251/6744kd41.